Literature DB >> 24189510

Diabetes: Immunotherapy for T1DM--still not there yet.

Raffaella Buzzetti1.   

Abstract

Alefacept, a fusion protein approved for psoriasis, has been trialled in patients with new-onset type 1 diabetes mellitus. However, the withdrawal of the drug from the US market and the unmet primary end point do not raise hope for this drug, even though some secondary end points were met and the study highlighted interesting immunological efficacy.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24189510     DOI： 10.1038/nrendo.2013.221

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  10 in total

1.  Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.

Authors:  Mark R Rigby; Linda A DiMeglio; Marc S Rendell; Eric I Felner; Jean M Dostou; Stephen E Gitelman; Chetanbabu M Patel; Kurt J Griffin; Eva Tsalikian; Peter A Gottlieb; Carla J Greenbaum; Nicole A Sherry; Wayne V Moore; Roshanak Monzavi; Steven M Willi; Philip Raskin; Antoinette Moran; William E Russell; Ashley Pinckney; Lynette Keyes-Elstein; Michael Howell; Sudeepta Aggarwal; Noha Lim; Deborah Phippard; Gerald T Nepom; James McNamara; Mario R Ehlers
Journal:  Lancet Diabetes Endocrinol       Date:  2013-09-23       Impact factor: 32.069

Review 2.  Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis.

Authors:  Gerald G Krueger
Journal:  Expert Opin Biol Ther       Date:  2002-04       Impact factor: 4.388

Review 3.  Clinical immunologic interventions for the treatment of type 1 diabetes.

Authors:  Lucienne Chatenoud; Katharina Warncke; Anette-G Ziegler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

4.  Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.

Authors:  C R Stiller; J Dupré; M Gent; M R Jenner; P A Keown; A Laupacis; R Martell; N W Rodger; B von Graffenried; B M Wolfe
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

5.  Remittive effects of intramuscular alefacept in psoriasis.

Authors:  Kenneth B Gordon; Richard G Langley
Journal:  J Drugs Dermatol       Date:  2003-12       Impact factor: 2.114

6.  Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus.

Authors:  R Assan; G Feutren; M Debray-Sachs; M C Quiniou-Debrie; C Laborie; G Thomas; L Chatenoud; J F Bach
Journal:  Lancet       Date:  1985-01-12       Impact factor: 79.321

7.  Insulin secretion in type 1 diabetes.

Authors:  Chynna Steele; William A Hagopian; Stephen Gitelman; Umesh Masharani; Melissa Cavaghan; Kristina I Rother; David Donaldson; David M Harlan; Jeffrey Bluestone; Kevan C Herold
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

8.  C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

Authors:  Jerry P Palmer; G Alexander Fleming; Carla J Greenbaum; Kevan C Herold; Lisa D Jansa; Hubert Kolb; John M Lachin; Kenneth S Polonsky; Paolo Pozzilli; Jay S Skyler; Michael W Steffes
Journal:  Diabetes       Date:  2004-01       Impact factor: 9.461

9.  Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.

Authors:  Carla J Greenbaum; Craig A Beam; David Boulware; Stephen E Gitelman; Peter A Gottlieb; Kevan C Herold; John M Lachin; Paula McGee; Jerry P Palmer; Mark D Pescovitz; Heidi Krause-Steinrauf; Jay S Skyler; Jay M Sosenko
Journal:  Diabetes       Date:  2012-06-11       Impact factor: 9.337

10.  Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.

Authors:  Kevan C Herold; Stephen E Gitelman; Mario R Ehlers; Peter A Gottlieb; Carla J Greenbaum; William Hagopian; Karen D Boyle; Lynette Keyes-Elstein; Sudeepta Aggarwal; Deborah Phippard; Peter H Sayre; James McNamara; Jeffrey A Bluestone
Journal:  Diabetes       Date:  2013-07-08       Impact factor: 9.461
  10 in total
  2 in total

Review 1.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

2.  β-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure.

Authors:  Ania Skowera; Kristin Ladell; David A Price; Mark Peakman; James E McLaren; Garry Dolton; Katherine K Matthews; Emma Gostick; Deborah Kronenberg-Versteeg; Martin Eichmann; Robin R Knight; Susanne Heck; Jake Powrie; Polly J Bingley; Colin M Dayan; John J Miles; Andrew K Sewell
Journal:  Diabetes       Date:  2014-09-23       Impact factor: 9.461
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.